{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:17:13Z","timestamp":1789345033307,"version":"build-2803163510"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>One in five chronic myeloid leukemia (CML) patients experiences such intolerability that they switch tyrosine kinase inhibitor (TKI) treatment within 3\u00a0years. Information on tolerability is needed to guide shared decision-making. However, an overview of symptoms patients experience per TKI is lacking, and physician-graded toxicity underestimates patients\u2019 experiences.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We systematically searched PubMed and Embase from inception to February 2025 and conducted a meta-analysis on the prevalence of patient-reported symptoms in CML per TKI. This study follows the Preferred Reporting Items for Systematic Reviews (PRISMA) guideline for systematic reviews.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We included 11 studies with 2987 patients, reporting on 47 different symptoms of any severity. The low-grade patient-reported symptom burden was high. No data were available on asciminib and ponatinib, and minimal data were available for bosutinib. In indirect, unadjusted comparisons, 13 out of 47 symptoms (of any severity) showed significant differences in prevalence between common TKI types.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings provide essential information to guide treatment decisions in cases of intolerability. However, there is a clear need for further research with standardized instruments, especially in second and third generation TKI types, including direct comparisons and comparisons adjusted for covariates.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09451-4","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T05:39:53Z","timestamp":1746250793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"33","author":[{"given":"Yolba","family":"Smit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pien","family":"Scheuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrthe P. M.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J. W. M.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardus F. M.","family":"Posthuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte L.","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella P. M. G.","family":"Hermens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M. A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"issue":"11","key":"9451_CR1","first-page":"1","volume":"9","author":"AS Abulafia","year":"2020","unstructured":"Abulafia AS, Shemesh S, Rosenmann L, Berger T, Leader A, Sharf G, Raanani P, Rozovski U (2020) Health-related quality of life in patients with chronic myeloid leukemia treated with first-versus second-generation tyrosine kinase inhibitors Journal of. Clin Med 9(11):1\u20139","journal-title":"Clin Med"},{"key":"9451_CR2","doi-asserted-by":"publisher","first-page":"e01005","DOI":"10.1002\/prp2.1005","volume":"10","author":"JA Adattini","year":"2022","unstructured":"Adattini JA, Gross AS, Wong Doo N, McLachlan AJ (2022) Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: an Australian experience. Pharmacol Res Perspect 10:e01005","journal-title":"Pharmacol Res Perspect"},{"key":"9451_CR3","unstructured":"Ali H, Mohamed Z, Abdullah D (2024) Health-related quality of life in chronic myeloid leukaemia patients receiving long-term therapy with different tyrosine kinase inhibitors in Kurdistan region Georgian Med News: 173\u2013180"},{"key":"9451_CR4","first-page":"42","volume":"7","author":"E Atallah","year":"2021","unstructured":"Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE (2021) Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial JAMA. Oncol 7:42\u201350","journal-title":"Oncol"},{"key":"9451_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3109\/10428194.2011.560310","volume":"52","author":"Z Aziz","year":"2011","unstructured":"Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A (2011) Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 52:1017\u20131023","journal-title":"Leuk Lymphoma"},{"key":"9451_CR6","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s00228-020-02910-3","volume":"76","author":"C Boons","year":"2020","unstructured":"Boons C, Timmers L, Janssen J, Westerweel PE, Blijlevens NMA, Smit WM, Bartelink IH, Wilschut JA, Swart EL, Hendrikse NH, Hugtenburg JG (2020) Response and adherence to nilotinib in daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib. Eur J Clin Pharmacol 76:1213\u20131226","journal-title":"Eur J Clin Pharmacol"},{"key":"9451_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/9780470743386","volume-title":"Introduction to meta-analaysis","author":"M Borenstein","year":"2009","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analaysis. John Wiley & Sons"},{"key":"9451_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.clml.2020.08.009","volume":"20","author":"H Bostan","year":"2020","unstructured":"Bostan H, Toptas T, Tanrikulu FP, Kut K, Arikan F, Yilmaz F, Atagunduz I, Firatli-Tuglular T (2020) Quality of life and symptom burden with first- and second-generation tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 20:836\u2013842","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"9451_CR9","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851\u20132857","journal-title":"J Clin Oncol"},{"key":"9451_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","volume":"11","author":"L Caldemeyer","year":"2016","unstructured":"Caldemeyer L, Dugan M, Edwards J, Akard L (2016) Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malig Rep 11:71\u201379","journal-title":"Curr Hematol Malig Rep"},{"key":"9451_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000362816","volume":"87","author":"D Cella","year":"2014","unstructured":"Cella D, Nowinski CJ, Frankfurt O (2014) The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology 87:133\u2013147","journal-title":"Oncology"},{"issue":"1","key":"9451_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40487-023-00255-2","volume":"12","author":"H Chen","year":"2024","unstructured":"Chen H, Wen Y, Zeng Y, Lin L, Sun B, Zhu H, He H, Wang X, Zou W, Zheng C, Zheng L, Pang L, Huang J, Zhang Y, Lin H, Zhu W, Wang Q, Zhou X, Liu X, Qu H, Liu Z, Du X, Xu N (2024) Patient versus physician perspective in the management of chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Oncology and Therapy 12(1):131\u2013145","journal-title":"Oncology and Therapy"},{"key":"9451_CR13","doi-asserted-by":"crossref","unstructured":"Cho HJ, Baek DW, Kim J, Jang YE, Lee Y, Moon JH, Sohn SK (2025) Real-world experience in the management of chronic myeloid leukemia patients focused on tyrosine kinase inhibitors intolerance and health-related quality of life Acta Haematol: 1\u201314","DOI":"10.1159\/000542562"},{"key":"9451_CR14","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s00432-019-02894-3","volume":"145","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brummendorf TH, Investigators BS (2019) Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. J Cancer Res Clin Oncol 145:1589\u20131599","journal-title":"J Cancer Res Clin Oncol"},{"key":"9451_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ajh.26463","volume":"97","author":"T Dahlen","year":"2022","unstructured":"Dahlen T, Edgren G, Ljungman P, Flygt H, Richter J, Olsson-Stromberg U, Wadenvik H, Dreimane A, Myhr-Eriksson K, Zhao J, Sjalander A, Hoglund M, Stenke L (2022) Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002\u20132017 in a complete coverage and nationwide agnostic register study. Am J Hematol 97:421\u2013430","journal-title":"Am J Hematol"},{"key":"9451_CR16","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Barate C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F (2011) Gimema health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118:4554\u20134560","journal-title":"Blood"},{"key":"9451_CR17","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/leu.2013.51","volume":"27","author":"F Efficace","year":"2013","unstructured":"Efficace F, Baccarani M, Breccia M, Cottone F, Alimena G, Deliliers GL, Barate C, Specchia G, Di Lorenzo R, Luciano L, Turri D, Martino B, Stagno F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Fava C, Veneri D, Sica S, Rambaldi A, Rosti G, Vignetti M, Mandelli F (2013) Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 27:1511\u20131519","journal-title":"Leukemia"},{"key":"9451_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","volume":"23","author":"F Efficace","year":"2014","unstructured":"Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F, Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F, Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G, Mandelli F (2014) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23:825\u2013836","journal-title":"Qual Life Res"},{"key":"9451_CR19","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1002\/cncr.31323","volume":"124","author":"F Efficace","year":"2018","unstructured":"Efficace F, Castagnetti F, Martino B, Breccia M, D\u2019Adda M, Angelucci E, Stagno F, Cottone F, Malato A, Trabacchi E, Capalbo SF, Gobbi M, Visani G, Salvucci M, Capodanno I, Tosi P, Tiribelli M, Scortechini AR, Levato L, Maino E, Binotto G, Gugliotta G, Vignetti M, Baccarani M, Rosti G (2018) Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. Cancer 124:2228\u20132237","journal-title":"Cancer"},{"key":"9451_CR20","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/10428194.2020.1838509","volume":"62","author":"F Efficace","year":"2021","unstructured":"Efficace F, Iurlo A, Patriarca A, Stagno F, Bee PC, Ector G, Capodanno I, Elena C, Bonifacio M, Blijlevens NMA, Caocci G, Wan C, Abruzzese E, Breccia M, Cottone F, Okumura I, Oerlemans S, Cascavilla N, Albano F, Kota V, Sztankay M, Miggiano MC, Saussele S, Di Renzo N, Sora F, Castagnetti F, Baccarani M, Vignetti M, Rosti G (2021) Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leuk Lymphoma 62:669\u2013678","journal-title":"Leuk Lymphoma"},{"key":"9451_CR21","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3324\/haematol.2013.093724","volume":"99","author":"F Efficace","year":"2014","unstructured":"Efficace F, Rosti G, Aaronson N, Cottone F, Angelucci E, Molica S, Vignetti M, Mandelli F, Baccarani M (2014) Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99:788\u2013793","journal-title":"Haematologica"},{"key":"9451_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41375-019-0563-0","volume":"34","author":"F Efficace","year":"2020","unstructured":"Efficace F, Stagno F, Iurlo A, Breccia M, Cottone F, Bonifacio M, Abruzzese E, Castagnetti F, Caocci G, Crugnola M, Capodanno I, Martino B, Tiribelli M, Patriarca A, Gozzini A, Pregno P, Saussele S, Cascavilla N, Fozza C, Bergamaschi M, Binotto G, Vignetti M, Rosti G (2020) Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia 34:488\u2013498","journal-title":"Leukemia"},{"key":"9451_CR23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","volume":"35","author":"L Eliasson","year":"2011","unstructured":"Eliasson L, Clifford S, Barber N, Marin D (2011) Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 35:626\u2013630","journal-title":"Leuk Res"},{"key":"9451_CR24","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s11136-021-02794-5","volume":"30","author":"S Foulon","year":"2021","unstructured":"Foulon S, Cony-Makhoul P, Guerci-Bresler A, Daban M, Kapso R, Tubert-Bitter P, Bonastre J (2021) Health state utility and quality of life measures in patients with chronic myeloid leukemia in France. Qual Life Res 30:2021\u20132032","journal-title":"Qual Life Res"},{"key":"9451_CR25","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","volume":"102","author":"IGP Geelen","year":"2017","unstructured":"Geelen IGP, Thielen N, Janssen J, Hoogendoorn M, Roosma TJA, Willemsen SP, Visser O, Cornelissen JJ, Westerweel PE (2017) Treatment outcome in a population-based, \u02bdreal-world\u2019 cohort of patients with chronic myeloid leukemia. Haematologica 102:1842\u20131849","journal-title":"Haematologica"},{"issue":"4","key":"9451_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5114\/wo.2023.135362","volume":"27","author":"K Gibek","year":"2023","unstructured":"Gibek K (2023) Side effects of treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukaemia and the occurrence of depressive symptoms. Wspolczesna Onkologia 27(4):277\u2013283","journal-title":"Wspolczesna Onkologia"},{"key":"9451_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.12740\/PP\/OnlineFirst\/152782","volume":"58","author":"K Gibek","year":"2024","unstructured":"Gibek K, Sacha T, Cyranka K (2024) Side effects of treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia and the occurrence of anxiety symptoms. Psychiatr Pol 58:25\u201338","journal-title":"Psychiatr Pol"},{"key":"9451_CR28","doi-asserted-by":"publisher","first-page":"e0234765","DOI":"10.1371\/journal.pone.0234765","volume":"15","author":"MC Grant","year":"2020","unstructured":"Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, Wade RG (2020) The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS One 15:e0234765","journal-title":"PLoS One"},{"issue":"2","key":"9451_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1053\/shem.2003.50039","volume":"40","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA (2003) Quality of life on imatinib. Semin Hematol 40(2):31\u201336. https:\/\/doi.org\/10.1053\/shem.2003.50039","journal-title":"Semin Hematol"},{"key":"9451_CR30","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O\u2019Brien SG, Dobrez DG, Hensley ML, Cella D, Investigators I (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21:2138\u20132146","journal-title":"J Clin Oncol"},{"key":"9451_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3466","author":"SJF Hermans","year":"2024","unstructured":"Hermans SJF, van der Maas NG, van Norden Y, Dinmohamed AG, Berkx E, Huijgens PC, Rivera DR, de Claro RA, Pignatti F, Versluis J, Cornelissen JJ (2024). Externally controlled studies using real-world data in patients with hematological cancers: a systematic review JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3466","journal-title":"Externally controlled studies using real-world data in patients with hematological cancers: a systematic review JAMA Oncol."},{"key":"9451_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/1471-2458-13-154","volume":"13","author":"R Herzog","year":"2013","unstructured":"Herzog R, Alvarez-Pasquin MJ, Diaz C, Del Barrio JL, Estrada JM, Gil A (2013) Are healthcare workers\u2019 intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review BMC Public Health 13:154","journal-title":"A systematic review BMC Public Health"},{"key":"9451_CR33","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen J, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saussele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984","journal-title":"Leukemia"},{"key":"9451_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjh.16145","volume":"187","author":"F Huguet","year":"2019","unstructured":"Huguet F, Cayuela JM, Cambier N, Carpentier N, Tindel M, Violet I, Zunic P, Lascaux A, Etienne G (2019) Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice. Br J Haematol 187:615\u2013626","journal-title":"Br J Haematol"},{"key":"9451_CR35","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/bmj.39343.408449.80","volume":"335","author":"JP Ioannidis","year":"2007","unstructured":"Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335:914\u2013916. https:\/\/doi.org\/10.1136\/bmj.39343.408449.80","journal-title":"BMJ"},{"issue":"10","key":"9451_CR36","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s00277-023-05394-0","volume":"102","author":"S Isfort","year":"2023","unstructured":"Isfort S, Manz K, Teichmann LL, Crysandt M, Burchert A, Hochhaus A, Saussele S, Kiani A, G\u00f6thert JR, Illmer T, Schafhausen P, Al-Ali HK, Stegelmann F, H\u00e4nel M, Pfeiffer T, Giagounidis A, Franke GN, Koschmieder S, Fabarius A, Ernst T, Warnken-Uhlich M, Wolber U, Kohn D, Pfirrmann M, Wolf D, Br\u00fcmmendorf TH (2023) Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) study. Ann Hematol 102(10):2741\u20132752. https:\/\/doi.org\/10.1007\/s00277-023-05394-0","journal-title":"Ann Hematol"},{"issue":"4","key":"9451_CR37","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4103\/2279-042X.128145","volume":"2","author":"P Jain","year":"2013","unstructured":"Jain P, Das VN, Ranjan A, Chaudhary R, Pandey K (2013) Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with imatinib or hydroxyurea. J Res Pharm Pract 2(4):156\u2013161. https:\/\/doi.org\/10.4103\/2279-042X.128145","journal-title":"J Res Pharm Pract"},{"key":"9451_CR38","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3324\/haematol.2020.247767","volume":"106","author":"L Janssen","year":"2021","unstructured":"Janssen L, Blijlevens NMA, Drissen M, Bakker EA, Nuijten MAH, Janssen J, Timmers S, Hopman MTE (2021) Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity. Haematologica 106:1876\u20131882","journal-title":"Haematologica"},{"key":"9451_CR39","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s00432-016-2159-7","volume":"142","author":"Q Jiang","year":"2016","unstructured":"Jiang Q, Liu ZC, Zhang SX, Gale RP (2016) Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol 142:1539\u20131547","journal-title":"J Cancer Res Clin Oncol"},{"key":"9451_CR40","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00432-017-2353-2","volume":"143","author":"Q Jiang","year":"2017","unstructured":"Jiang Q, Wang HB, Yu L, Gale RP (2017) Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy. J Cancer Res Clin Oncol 143:1013\u20131022","journal-title":"J Cancer Res Clin Oncol"},{"key":"9451_CR41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/cncr.31082","volume":"124","author":"HM Kantarjian","year":"2018","unstructured":"Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, Brummendorf TH, Su Y, Reisman AL, Shapiro M, Lipton JH (2018) Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer 124:587\u2013595","journal-title":"Cancer"},{"key":"9451_CR42","doi-asserted-by":"publisher","unstructured":"Kapoor J, Agrawal N, Ahmed R, Sharma SK, Gupta A, Bhurani D (2015) Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study Mediterranean Journal of Hematology and Infectious Diseases 7(1) (no pagination). https:\/\/doi.org\/10.4084\/MJHID.2015.013","DOI":"10.4084\/MJHID.2015.013"},{"key":"9451_CR43","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2147\/PPA.S92125","volume":"9","author":"M Kekale","year":"2015","unstructured":"Kekale M, Peltoniemi M, Airaksinen M (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 9:1733\u20131740. https:\/\/doi.org\/10.2147\/PPA.S92125","journal-title":"Patient Prefer Adherence"},{"key":"9451_CR44","first-page":"142","volume":"30","author":"H Menon","year":"2017","unstructured":"Menon H (2017) Non-adherence to CML therapy and its clinical implications in India. Natl Med J India 30:142\u2013147","journal-title":"Natl Med J India"},{"key":"9451_CR45","first-page":"59","volume":"127","author":"CB Migliavaca","year":"2020","unstructured":"Migliavaca CB, Stein C, Colpani V, Munn Z, Falavigna M (2020) Prevalence estimates reviews - systematic review methodology G. Quality assessment of prevalence studies: a systematic review J Clin Epidemiol 127:59\u201368","journal-title":"Quality assessment of prevalence studies: a systematic review J Clin Epidemiol"},{"key":"9451_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12185-024-03805-0","volume":"120","author":"Y Minami","year":"2024","unstructured":"Minami Y, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, Kubo K, Goto T, Kirito K, Maki A, Aoki M, Dawson MK, Matsumura I (2024) Asciminib in patients with CML-CP previously treated with \u2265 2 tyrosine kinase inhibitors: 96-week results from the Japanese subgroup analysis of the ASCEMBL study. Int J Hematol 120:305\u2013313","journal-title":"Int J Hematol"},{"key":"9451_CR47","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/bmt.2013.232","volume":"49","author":"XD Mo","year":"2014","unstructured":"Mo XD, Jiang Q, Xu LP, Liu DH, Liu KY, Jiang B, Jiang H, Chen H, Chen YH, Zhang XH, Han W, Wang Y, Huang XJ (2014) Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant 49:576\u2013580","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"9451_CR48","doi-asserted-by":"publisher","first-page":"e0147601","DOI":"10.1371\/journal.pone.0147601","volume":"11","author":"PA Modesti","year":"2016","unstructured":"Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, Perruolo E, Parati G, ESH Working Group on CV Risk in Low Resource Settings (2016) Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS One 11(1):e0147601. https:\/\/doi.org\/10.1371\/journal.pone.0147601","journal-title":"PLoS One"},{"key":"9451_CR49","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s11136-021-02952-9","volume":"31","author":"CTT Nguyen","year":"2022","unstructured":"Nguyen CTT, Nguyen BT, Nguyen TTT, Petrelli F, Scuri S, Grappasonni I (2022) Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors. Qual Life Res 31:733\u2013743","journal-title":"Qual Life Res"},{"key":"9451_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-021-06408-1","volume":"30","author":"LB Oswald","year":"2022","unstructured":"Oswald LB, Hyland KA, Eisel SL, Hoogland AI, Knoop H, Nelson AM, Pinilla-Ibarz J, Sweet K, Jacobsen PB, Jim HSL (2022) Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy. Support Care Cancer 30:87\u201394","journal-title":"Support Care Cancer"},{"key":"9451_CR51","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed) 74:790\u2013799","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"9451_CR52","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00520-012-1630-5","volume":"21","author":"KM Phillips","year":"2013","unstructured":"Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB (2013) Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 21:1097\u20131103","journal-title":"Support Care Cancer"},{"issue":"Supplement 1","key":"9451_CR53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.achaem.2015.07.321","volume":"46","author":"A Piekarska","year":"2015","unstructured":"Piekarska A, Gil L, Jakitowicz K, Prejzner W, Komarnicki M, Hellmann A (2015) Quality of life in CML patients after HCT pretreated with second generation tyrosine kinase inhibitors. Acta Haematol Pol 46(Supplement 1):193\u2013194","journal-title":"Acta Haematol Pol"},{"issue":"2","key":"9451_CR54","first-page":"2784","volume":"12","author":"AA Rashid","year":"2020","unstructured":"Rashid AA, Albasry Z (2020) Assessing the quality of life in imatinib-treated chronic myeloid leukemia patients: a cross sectional descriptive study. Intern J Pharm Res 12(2):2784\u20132791","journal-title":"Intern J Pharm Res"},{"key":"9451_CR55","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41375-023-01888-y","volume":"37","author":"D Rea","year":"2023","unstructured":"Rea D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, D\u2019Alessio D, Wu Y, Lawrance R, Narbutas S, Sharf G, Hochhaus A (2023) Health-related quality of life of patients with resistant\/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia 37:1060\u20131067","journal-title":"Leukemia"},{"key":"9451_CR56","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41375-023-02080-y","volume":"38","author":"G Rosti","year":"2024","unstructured":"Rosti G, Br\u00fcmmendorf TH, Gjertsen BT, Giraldo-Castellano P, Castagnetti F, Gambacorti-Passerini C, Ernst T, Zhao H, Kuttschreuter L, Purcell S, Giles FJ, Hochhaus A (2024) Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study. Leukemia 38:126\u2013135","journal-title":"Leukemia"},{"key":"9451_CR57","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.clml.2017.01.001","volume":"17","author":"T Sacha","year":"2017","unstructured":"Sacha T, Gora-Tybor J, Wasak-Szulkowska E, Kyrcz-Krzemien S, Medras E, Becht R, Bober G, Kotowska A, Waclaw J, Hellmann A (2017) Quality of life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second-line therapy: a multicenter prospective observational study. Clin Lymphoma Myeloma Leuk 17:283\u2013295","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"9451_CR58","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE (2015) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2:e186-193","journal-title":"Lancet Haematol"},{"key":"9451_CR59","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11899-021-00656-y","volume":"16","author":"KL Schoenbeck","year":"2021","unstructured":"Schoenbeck KL, Flynn KE (2021) Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: current state and future directions. Curr Hematol Malig Rep 16:491\u2013499","journal-title":"Curr Hematol Malig Rep"},{"key":"9451_CR60","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","volume":"34","author":"G Sharf","year":"2020","unstructured":"Sharf G, Marin C, Bradley JA, Pemberton-Whiteley Z, Bombaci F, Christensen RIO, Gouimi B, Deekes NB, Daban M, Geissler J (2020) Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia 34:2102\u20132112","journal-title":"Leukemia"},{"key":"9451_CR61","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1080\/10428194.2020.1842397","volume":"62","author":"D Shi","year":"2021","unstructured":"Shi D, Li Z, Li Y, Jiang Q (2021) Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Leuk Lymphoma 62:640\u2013648","journal-title":"Leuk Lymphoma"},{"key":"9451_CR62","doi-asserted-by":"publisher","unstructured":"Smit Y, Metsemakers S, Janssen J, Posthuma EFM, Walraven I, Hermens R, Blijlevens NMA (2023) Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures Lancet Haematol. https:\/\/doi.org\/10.1016\/S2352-3026(23)00173-4","DOI":"10.1016\/S2352-3026(23)00173-4"},{"key":"9451_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1037\/10382-001","volume-title":"Adaptation to changing health: response shift in quality-of-life research","author":"MAG Sprangers","year":"2000","unstructured":"Sprangers MAG, Schwartz CE (2000) Integrating response shift into health-related quality-of-life research: a theoretical model. In: Sprangers MAG, Schwartz CE (eds) Adaptation to changing health: response shift in quality-of-life research. American Psychological Association, pp 11\u201323"},{"key":"9451_CR64","first-page":"e2400281","volume":"10","author":"F Tadesse","year":"2024","unstructured":"Tadesse F, Sparano F, Gebremedhin A, Abubeker A, Piciocchi A, Cipriani M, Krepper D, Gemechu L, Mulu A, Asres G, Efficace F (2024) Health-related quality of life and financial burden in Ethiopian patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: a cross-sectional study JCO Glob. Oncol 10:e2400281","journal-title":"Oncol"},{"key":"9451_CR65","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S2352-3026(22)00045-X","volume":"9","author":"G Thanarajasingam","year":"2022","unstructured":"Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM (2022) Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 9:e374\u2013e384","journal-title":"Lancet Haematol"},{"issue":"26","key":"9451_CR66","doi-asserted-by":"publisher","first-page":"e11322","DOI":"10.1097\/MD.0000000000011322","volume":"97","author":"YF Tsai","year":"2018","unstructured":"Tsai YF, Huang WC, Cho SF, Hsiao HH, Liu YC, Lin SF, Liu TC, Chang CS (2018) Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan medicine. Medicine (Baltimore) 97(26):e11322. https:\/\/doi.org\/10.1097\/MD.0000000000011322","journal-title":"Medicine (Baltimore)"},{"key":"9451_CR67","doi-asserted-by":"publisher","unstructured":"Uyanik MS, Pamuk GE, Maden M, Merev E, Cevik G, Uyanik V, Umit EG, Demir AM, Akker M (2017) The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients. Eur J Cancer Care (Engl) 26(2). https:\/\/doi.org\/10.1111\/ecc.12423","DOI":"10.1111\/ecc.12423"},{"key":"9451_CR68","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","volume":"122","author":"LA Williams","year":"2013","unstructured":"Williams LA, Garcia Gonzalez AG, Ault P, Mendoza TR, Sailors ML, Williams JL, Huang F, Nazha A, Kantarjian HM, Cleeland CS, Cortes JE (2013) Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 122:641\u2013647","journal-title":"Blood"},{"key":"9451_CR69","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood.2021014689","volume":"139","author":"DT Yeung","year":"2022","unstructured":"Yeung DT, Shanmuganathan N, Hughes TP (2022) Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. Blood 139:3474\u20133479","journal-title":"Blood"},{"key":"9451_CR70","doi-asserted-by":"publisher","first-page":"e18079","DOI":"10.1097\/MD.0000000000018079","volume":"98","author":"L Yu","year":"2019","unstructured":"Yu L, Huang X, Gale RP, Wang H, Jiang Q (2019) Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Medicine (Baltimore) 98:e18079","journal-title":"Medicine (Baltimore)"},{"key":"9451_CR71","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1186\/s12885-018-4699-5","volume":"18","author":"L Yu","year":"2018","unstructured":"Yu L, Wang H, Milijkovic D, Huang X, Jiang Q (2018) Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study. BMC Cancer 18:782","journal-title":"BMC Cancer"},{"key":"9451_CR72","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00432-021-03832-y","volume":"148","author":"F Zheng","year":"2022","unstructured":"Zheng F, Dou X, Zhang L, Jin J, Zhang Y, Liu B, Meng L, Zhu X, Lu Z, Jia Y, Liu H, Lin H, Zhou L, Zhao X, Yang W, Sun H, Qian S, Ma H, Wu R, Zhang L, Jiang Q (2022) Health-related quality of life in children with chronic myeloid leukemia in the chronic phase. J Cancer Res Clin Oncol 148:341\u2013350","journal-title":"J Cancer Res Clin Oncol"},{"key":"9451_CR73","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1002\/cam4.1808","volume":"7","author":"A Zulbaran-Rojas","year":"2018","unstructured":"Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O\u2019Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H (2018) A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med 7:5457\u20135469","journal-title":"Cancer Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09451-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09451-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T05:02:58Z","timestamp":1746853378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09451-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["9451"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09451-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding bodies had no role in the design of the study, collection and analysis of data, or the  decision to publish.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"Authors declare the following potential conflicts of interest: CB, no conflicts of interest. EP: research support: AbbVie, AstraZeneca and Janssen. JJ: research support from Abbvie, AstraZeneca, Janssen, Novartis, and BMS; honoraria from Pfizer, Novartis, Incyte, and Abbvie; and is the founder of Apps for Care and Science Foundation and developer of the HematologyApp. The Apps for Care and Science Foundation non-profit organization is supported by Abbvie, AstraZeneca, Amgen, Sanofi-Genzyme, Takeda, Jazz, Roche, Servier, BMS\/Celgene, Daiichi-Sankyo, Janssen, and Incyte. ML, no conflicts of interest. NB, no conflicts of interest. RH, research support: AbbVie, AstraZeneca and Janssen. PS, no conflicts of interest. YS, research support: AbbVie, AstraZeneca and Janssen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"446"}}